window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

FDA accelerated approval

  • Biologics & Biosimilars,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Global health,Medical devices,Pharmaceuticals and therapeutics,Regulatory Affairs

    Hansa Biopharma reports statistically significant improvement in kidney function, supporting planned BLA submission

    Hansa Biopharma AB has announced positive topline results from the [...]

    September 26, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome
    Categories: Central Nervous System, Clinical Development, Drug Delivery & Formulation, Drug Development, Neurosciences, Patient Centricity
  • Currax highlights peer-reviewed review supporting combination approaches in obesity treatment
    Categories: Obesity, Pharmaceuticals and therapeutics, Research & Development
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical Development, Clinical studies, Hematology, Regulatory Affairs, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top